Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Up Today?

Why TLX stock is up today

Telix Pharmaceuticals ADR (TLX) surged 6.73% to $11.58 in early trading on Friday. The stock’s sharp rise followed the completion of enrollment in its Phase 3 BiPASS study and confirmation of alignment with the FDA on the NDA pathway. These developments have reinforced investor confidence in the company’s regulatory and commercial prospects.

What Happened

Telix Pharmaceuticals completed enrollment of 350 patients in its Phase 3 BiPASS study, a key milestone for the company’s lead program. This study is evaluating a pre-biopsy prostate cancer imaging agent. The company also confirmed alignment with the FDA on the pathway for the New Drug Application, a critical step toward potential approval. These developments were highlighted in multiple reports and contributed to a strong open. H.C. Wainwright reiterates its Buy rating on the stock with a $20 price target, while Wedbush also maintains an Outperform rating with a $22 price target. Telix also announced David Gill as its new board chair following Mark Nelson’s transition from the interim role.

What The Data Shows

The stock opened with a 3.9% gap up at $11.27, reaching a session high of $11.60 shortly after the market opened. Trading volume so far is 0.0M shares, which is 0.2 times the 3-month daily average. The stock is currently near its 52-week high of $12.48 and has printed five fresh 52-week highs on September 2, 2026. Telix’s fundamentals show a market cap of $3.7B, a P/E ratio of 113.7, and revenue growth of 33.5% in the trailing twelve months. The company also guides for FY 2026 revenue of $950M to $970M, with total income above $1B.

What To Watch

Telix’s upcoming regulatory milestones and potential approval decisions will be key to monitor. Investors should also track coverage breadth and any further updates on the BiPASS study or NDA process.